PTPRC and breast carcinoma: SET-CTCs were immunocytochemically analysed as nucleated cells (DAPI-positive) > 10 μm in diameter that stained with anti-SET (green) antibody, but not with anti-CD45 antibody (red) in patients with breast cancer (Fig. 4a).